Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HB1801 + SG001 + cisplatin with concurrent radiotherapy versus paclitaxel + cisplatin with concurrent radiotherapy in unresectable locally advanced esophageal squamous cell carcinoma
CTR20233614Phase 2Active
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology
- Start
- Mar 2024
- Modality
- Small Molecules, Nanoparticles → Drug Delivery Systems, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of albumin-bound docetaxel, PBI-1308 in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by CSPC ZhongQi Pharmaceutical Technology. Started Mar 2024; status: active.
02
Drugs
albumin-bound docetaxelPBI-1308
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on CTR20233614.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20233614.